RE: On the verge ....22 Jul 2025 15:18
I think the issue with Scancell is worth looking at as its a warning to what CAN happen with poor leadership, the reality is the UK market sucks monkey balls for raising cash, your going to get a dose of sandy KY Jelly if you keep doing it. I did not look at the science, AI tells me what they have looks like a significant improvement over standard of care which is good. It also says a licence there could be 100s of millions. So yea science looks good, no arguments or complaints. And I am NOT deramping them or saying anything negative, HOWEVER look at their books and you see why their SP is struggling, first they are valued at 100m, so not insignificant and certainly more than 1000% our mCap. Next placings... We have raised around 2m this year, they have raised over 14 million and their interim results show they are burning though that. We struggled to raise 400k a month in Hemo so of course raising that much is going to lead to difficulties. Then there is the Convertible Loan Notes, yes they have CLNs with a face value of 20m but their paper liability is an additional 10m+ in reality until converted nobody knows the true impact they will have, here it took our SP from 10P+ down to 2.5p and wiped like 50m off our mCap.
Its not about excellent RNS's
Its not about good clinical results.
Its not about PR or social media.
Its all about the dilution. Are you dumping more shares onto the open market via traders who short sell or flip than the market can accept? If the answer is yes then your SP will fall.
The main reason people buy these secondary shares is FOMO that a big licencing deal etc will land so its better to take the pain and buy up the stock and pray for news. And the Company have to persuade enough people to buy to swallow the load. Scancell are were Hemo was 6 months ago, increasing overheads with a fully saturated market. And there they are already 100m+ so upside is not that great.
Dr Sandler recognised this, he had 2 options, persuade the market to buy more OR Slash his costs. Its very simple maths, less shares + more people buying = increase in share price. People think the SP has magically risen here for no reason? The SP was being artificially depressed by traders and shorters using limit trades to push the SP down, all those 1.5k A trades? THEY WERE DELIBERATE.
Vlad was raising 400k a month and these traders knew it was more than the market could absorb, we were an easy target.
Now? Vlad has slashed costs, he has signed up for G-REX allowing him to fund raise via selling his services.
This is NOT the same Hemogenyx as 6 months ago. There is a reason the trolls were out en-force over the weekend, they KNEW that Hemo was no longer an easy short.
Hemogenyx WAS an easy target, it WAS battered daily, it WAS haemorrhaging more money than they could raise.
Now? We can all breath, let the science do the talking, Vlad has steadied the ship, Well done Vlad!! This is what we want to see from a CEO.